DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Pegbelfermin

Generic Name: Pegbelfermin

Drug Type: Biotech

CAS Number: 2089039-22-3

Unique Ingredient Identifier: P5T1E46W5D

Overview

Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).

Background

Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

Phase 1

Completed

Posted: 2020/11/18

Sponsor:Bristol-Myers Squibb

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Phase 1

Completed

Posted: 2020/07/30

Sponsor:Bristol-Myers Squibb

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

Phase 1

Completed

Posted: 2018/09/17

Sponsor:Bristol-Myers Squibb

Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

Completed

Posted: 2018/08/02

Sponsor:Meridian Bioscience,...

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

Phase 2

Completed

Posted: 2018/04/03

Sponsor:Bristol-Myers Squibb

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies

6 months ago

The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Madrigal's Resmetirom Nears Full Approval for NASH Cirrhosis Treatment Following Phase 3 Enrollment Completion

8 months ago

Madrigal Pharmaceuticals completed patient enrollment for its MAESTRO-NASH OUTCOMES trial, evaluating resmetirom for compensated NASH cirrhosis.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy